Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2001, p. 101-106, Vol. 39, No. 1
Department of Dermatology, Juntendo
University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
Received 14 April 2000/Returned for modification 31 May
2000/Accepted 17 October 2000
An internal partial sequence of the gene encoding actin
(ACT), 725 to 762 bp in length, was amplified by PCR from
the genomic DNA extract of 12 species of dermatophytes and sequenced.
An intron that is 56 to 93 bp in length was located along the
ACT fragment of all of the dermatophytes at codon position
301 (
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.1.101-106.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Isolation of an Intron-Containing Partial Sequence
of the Gene Encoding Dermatophyte Actin (ACT) and Detection
of a Fragment of the Transcript by Reverse Transcription-Nested PCR as
a Means of Assessing the Viability of Dermatophytes in Skin
Scales
3) (a codon number followed by "
3" indicates that the
intron directly follows the codon) with reference to the amino acid
sequence of human
-smooth muscle actin. A primer pair that annealed
to exon sequences flanking the ACT-associated intron
produced a dermatophyte-specific 171-bp amplicon by reverse
transcription-nested PCR (RT-PCR) of dermatophyte ACT mRNA.
PCR primer pairs with antisense sequence based on the ACT
intron sequence were species specific for dermatophytes, suggesting a
potential for use in the identification of dermatophytes. The viability
of dermatophytes in skin scales was subsequently assessed by the
presence of ACT mRNA in total RNA extracted from a 48-h
culture of scale samples in 250 µl of yeast carbon base broth.
RT-nested PCR of dermatophyte-infected samples amplified an
ACT fragment of the predicted size of 171 bp. The results
of viability testing based on ACT mRNA detection by
RT-nested PCR correlated with cultural isolation from skin scales. This
method is a potential tool for rapidly assessing fungal viability in the therapeutic efficacy testing of antimycotics.
*
Corresponding author. Mailing address: Department of
Dermatology, Juntendo University School of Medicine, 2-1-1 Hongo,
Bunkyo-ku, Tokyo 113, Japan. Phone: 81-3-5802-1089. Fax:
81-3-3813-9443. E-mail: tsuboi{at}med.juntendo.ac.jp.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»